Nicainoprol
1991; Wiley; Volume: 9; Issue: 3 Linguagem: Italiano
10.1111/j.1527-3466.1991.tb00413.x
ISSN1527-3466
AutoresSunao Imanishi, Tatsunori Kimura, Makoto Arita,
Tópico(s)Analytical Chemistry and Sensors
ResumoCardiovascular Drug ReviewsVolume 9, Issue 3 p. 223-236 Free to Read Nicainoprol Sunao Imanishi, Corresponding Author Sunao Imanishi Department of Physiology, Faculty of Medicine, Medical College of Oita, Oita, JapanAddress correspondence and reprint requests to Dr. S. Imanishi, at Department of Physiology, Faculty of Medicine, Medical College of Oita, Hasama, Oita 879-55, Japan.Search for more papers by this authorTatsunori Kimura, Tatsunori Kimura Department of Physiology, Faculty of Medicine, Medical College of Oita, Oita, JapanSearch for more papers by this authorMakoto Arita, Makoto Arita Department of Physiology, Faculty of Medicine, Medical College of Oita, Oita, JapanSearch for more papers by this author Sunao Imanishi, Corresponding Author Sunao Imanishi Department of Physiology, Faculty of Medicine, Medical College of Oita, Oita, JapanAddress correspondence and reprint requests to Dr. S. Imanishi, at Department of Physiology, Faculty of Medicine, Medical College of Oita, Hasama, Oita 879-55, Japan.Search for more papers by this authorTatsunori Kimura, Tatsunori Kimura Department of Physiology, Faculty of Medicine, Medical College of Oita, Oita, JapanSearch for more papers by this authorMakoto Arita, Makoto Arita Department of Physiology, Faculty of Medicine, Medical College of Oita, Oita, JapanSearch for more papers by this author First published: September 1991 https://doi.org/10.1111/j.1527-3466.1991.tb00413.xCitations: 9AboutPDF ToolsRequest permissionExport citationAdd to favoritesTrack citation ShareShare Give accessShare full text accessShare full-text accessPlease review our Terms and Conditions of Use and check box below to share full-text version of article.I have read and accept the Wiley Online Library Terms and Conditions of UseShareable LinkUse the link below to share a full-text version of this article with your friends and colleagues. Learn more.Copy URL Share a linkShare onEmailFacebookTwitterLinkedInRedditWechat REFERENCES 1 Bohn H, Kaiser J, Göbel H, Martorana PA, Scholtholt J, Nitz RE. Pharmacological effects of nicainoprol (1-nicotinyl-8-(3-isopropylamino-2-hydroxy-propoxy)-tetrahydroquinoline), a novel antiarrhythmic drug [Abstract]. Naunyn Schmiedebergs Arch Pharmacol 1985; 329(suppl): R55. Google Scholar 2 Campbell T. The clinical relevance of the subclassification of class I antiarrhythmic drugs. In: J Toyama, LM Hondeghem, eds. Current topics in antiarrhythmic agents. Tokyo : Excerpta Medica, 1989: 201–12. Google Scholar 3 Coetzee WA, Opie LH, Saman S. Proposed role of energy supply in the genesis of delayed afterdepolarizations—implications for ischemic or reperfusion arrhythmias. J Moll Cell Cardiol 1987; 19(suppl V): 13–21. 10.1016/S0022-2828(87)80606-5 CASWeb of Science®Google Scholar 4 Courtney KR. Interval-dependent effects of antiarrhythmic drugs on excitability of guinea-pig myocardium. J Moll Cell Cardiol 1980; 12: 1273–86. 10.1016/0022-2828(80)90071-1 CASPubMedWeb of Science®Google Scholar 5 Hamon G, Fortin M, Worcel M. β-Blocking properties of nicainoprol and propafenone [Abstract]. Eur Heart J 1984; 5(suppl 1): 131. PubMedWeb of Science®Google Scholar 6 Hamon G, Lusamvuku NAT, Worcel M. The cellular electrophysiological effects of nicainoprol on dog isolated cardiac tissues, comparison with reference drugs [Abstract]. Br J Pharmacol 1984; 81(suppl): 79p. Google Scholar 7 Hashimoto K, Akiyama K, Mitsuhashi H. Antiarrhythmic effect of a new class 1 antiarrhythmic drug, nicainoprol, on canine ventricular arrhythmias. Jpn J Pharmacol 1989; 49: 245–54. 10.1254/jjp.49.245 CASPubMedWeb of Science®Google Scholar 8 Hondeghem LM, Katzung BG. Time- and voltage-dependent interactions of antiarrhythmic drugs with cardiac sodium channels. Biochem Biophys Acta 1977; 472: 373–98. 10.1016/0304-4157(77)90003-X CASPubMedWeb of Science®Google Scholar 9 Horai Y, Ishizaki T. Determination of nicainoprol, a new antiarrhythmic agent, in human plasma and urine by high-performance liquid chromatography. J Chromatogr 1986; 383: 103–10. 10.1016/S0378-4347(00)83446-5 CASPubMedWeb of Science®Google Scholar 10 Imanishi S, Morita S, Arita M. Electrophysiological effects of AN-132, a new antiarrhythmic compound, in guinea pig papillary muscles. J Cardiovasc Pharmacol 1990; 15: 476–84. 10.1097/00005344-199003000-00019 CASPubMedWeb of Science®Google Scholar 11 Ishizaki T. Pharmacokinetics and pharmacodynamics of nicainoprol, a new class I antiarrhythmic agents. In: J Toyama, LM Hondeghem, eds. Current topics in antiarrhythmic agents. Tokyo : Excerpta Medica, 1989: 269–72. Web of Science®Google Scholar 12 Ishizaki T, Horai Y, Kubota K, Minegishi A, Echizen H, Chiba K. Disposition kinetics and dynamics of nicainoprol, a new antiarrhythmic agent, in humans. Clin Pharmacol Ther 1987; 42: 525–34. 10.1038/clpt.1987.192 CASPubMedWeb of Science®Google Scholar 13 Kimura T, Imanishi S, Arita M. Electrophysiologic effects of nicainoprol, a putative class I antiarrhythmic agent, on the guinea pig ventricular papillary muscle. J Cardiovasc Pharmacol 1989; 13: 767–73. 10.1097/00005344-198905000-00013 CASPubMedWeb of Science®Google Scholar 14 Libersa CC, Caron JF, Kacet S, et al. Electrophysiological effects of intravenous nicainoprol, a new antiarrhythmic agent, in 11 patients. Eur Heart J 1988; 9: 271–8. CASPubMedWeb of Science®Google Scholar 15 Linz W, Petry P, Schölkens BA, Martorana PA. Ramiprilat and nicainoprol reduce reperfusion arrhythmias in the isolated ischemic working rat heart [Abstract]. J Moll Cell Cardiol 1986; 18(suppl 2): 68. Google Scholar 16 Martorana PA, Linz W, Göbel H, Petry P, Schölkens BA. Effects of nicainoprol on reperfusion arrhythmia in the isolated working rat heart and on ischemia and reperfusion arrhythmia and myocardial infarct size in the anesthetized rat. Eur J Pharmacol 1987; 143: 391–401. 10.1016/0014-2999(87)90463-8 CASPubMedWeb of Science®Google Scholar 17 Mason JW. Basic and clinical cardiac electrophysiology of encainide. Am J Cardiol 1986; 58: 18C–24. 10.1016/0002-9149(86)90099-8 CASPubMedWeb of Science®Google Scholar 18 McLeod AA, Stilles GL, Shand DG. Demonstration of beta-adrenoceptor blockade by propafenone hydrochloride: clinical pharmacologie, radiological binding and adenylate cyclase activation studies. Clin Pharmacol Ther 1984; 228: 461–6. CASPubMedWeb of Science®Google Scholar 19 Pottage A. Clinical profiles of newer class I antiarrhythmic agents—tocainide, mexiletine, encainide, flecainide and lorcainide. Am J Cardiol 1983; 52: 24C–31. 10.1016/0002-9149(83)90628-8 CASPubMedWeb of Science®Google Scholar 20 Sawanobori T, Hirano Y, Adaniya H, Yamashita K, Hayami H, Hiraoka M. Electrophysiological effect of new antiarrhythmic drug—nicainoprol—on the various cardiac tissues. Heart 1987; 19: 937–43 (in Japanese). Google Scholar 21 Sen S, Rettig G, Özbek C, Fröhlig G, Schieffer H, Bette L. Electrophysiological and clinical efficacy of nicainoprol in supraventricilar tachycardia [Abstract]. Circulation 1986; 74(suppl): II–99. Google Scholar 22 Sen S, Rettig G, Özbek C, Fröhlig G, Schieffer H, Bette L. Electrophysiological effects of new antiarrhythmic agent, nicainoprol, in humans. J Cardiovasc Pharmacol 1986; 8: 144–50. 10.1097/00005344-198601000-00021 CASPubMedWeb of Science®Google Scholar 23 Sen S, Rettig G, Schieffer H, Bette L. Dose-related effects of nicainoprol (CAS 924) on invasive electrophysiological parameters in patients with and without conduction abnormalities. Z Kardiol 1988; 77: 600–7. CASPubMedWeb of Science®Google Scholar 24 Starmer CF, Grant AO, Strauss HC. Mechanisms of use-dependent block of sodium channels in excitable membranes by local anesthetics. Biophys J 1984; 46: 15–27. 10.1016/S0006-3495(84)83994-6 CASPubMedWeb of Science®Google Scholar 25 Tonet JL, Frank R, Fontaine G, Grosgogeat Y. Electrophysiologic effects of nicainoprol, a new antiarrhythmic drug [Abstract]. Acta Pharmacol Toxicol 1986; 59(suppl 5): 288. Google Scholar 26 Vaughan Williams EM. A classification of antiarrhythmic actions reassessed after a decade of new drugs. J Clin Pharmacol 1984; 24: 129–47. 10.1002/j.1552-4604.1984.tb01822.x CASPubMedWeb of Science®Google Scholar 27 Voigt W, Mannhold R, Limberg J, Blaschke G. Interactions of antiarrhythmics with artificial phospholipid membranes. J Pharm Sci 1988; 77: 1018–20. 10.1002/jps.2600771206 CASPubMedWeb of Science®Google Scholar 28 Weirich J, Antoni H. Evaluation and interpretation of voltage- and frequency-dependent electrophysiologic effects of a new class I antiarrhythmic agent (nicainoprol) on guinea pig papillary muscle and isolated heart. J Cardiovasc Pharmacol 1988; 12: 664–71. 10.1097/00005344-198812000-00007 CASPubMedWeb of Science®Google Scholar 29 Weirich J, Antoni H. Modelling frequency- and voltage-dependent effects of class I antiarrhythmic drug (nicainoprol) on ±max of the cardiac action potential from guinea-pig papillary muscle. Naunyn Schmiedebergs Arch Pharmacol 1989; 340: 456–64. 10.1007/BF00167049 CASPubMedWeb of Science®Google Scholar Citing Literature Volume9, Issue3September 1991Pages 223-236 ReferencesRelatedInformation
Referência(s)